Recent Research Analysts’ Ratings Changes for Apogee Therapeutics (APGE)

A number of firms have modified their ratings and price targets on shares of Apogee Therapeutics (NASDAQ: APGE) recently:

• 5/28/2026 – Apogee Therapeutics was given a new $89.00 price target by The Goldman Sachs Group, Inc..
• 5/28/2026 – Apogee Therapeutics was upgraded by The Goldman Sachs Group, Inc. to “hold”.
• 5/27/2026 – Apogee Therapeutics had its price target lowered by Truist Financial Corporation from $83.00 to $81.00. They now have a “hold” rating on the stock.
• 5/27/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $137.00 price target on the stock.
• 5/27/2026 – Apogee Therapeutics had its price target raised by Wedbush from $120.00 to $135.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – Apogee Therapeutics is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $140.00 price target on the stock.
• 5/1/2026 – Apogee Therapeutics is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $140.00 price target on the stock.
• 4/20/2026 – Apogee Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the transaction, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $84.14, for a total transaction of $462,770.00. Following the transaction, the insider directly owned 207,023 shares in the company, valued at $17,418,915.22. This trade represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,000 shares of company stock worth $5,718,390 over the last ninety days. 24.30% of the stock is owned by insiders.

Get Apogee Therapeutics Inc alerts:

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

Featured Articles

• Five stocks we like better than Apogee Therapeutics
• The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
• Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
• Medtronic Bottoms, Healthy Rebound Ahead
• GitLab’s Price Recovery Gains Traction—Time to Get On Board?

Receive News & Ratings for Apogee Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.